| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
We successfully generated chimeric antigen receptor (CAR)-modified T cells using piggyBac transposon and nucleofection systems, and efficiently expanded the CAR-T cells using a serum-free culture system.
GD2-specific CAR-T cells induced in vitro cell death to various extents against GD2-positive tumor cell lines (neuroblastoma, retinoblastoma, medulloblastoma, and glioblastom). Additionally, addition of the agent A markedly increased the anti-tumor ability.
Considering the simplicity, safety, and cost-benefit of non-viral gene modification, piggyBac transposon-based GD2-specific T-cell therapy may be a novel therapeutic option against pediatric neurogenic tumors.
|
